ResMed CEO Michael Farrell于2026年3月9日出售股票125万美元, 股份减少了1.06%, ResMed CEO Michael Farrell sold $1.25M in stock on March 9, 2026, reducing his stake by 1.06%, as the company reported strong earnings despite a stock dip.

CEO Michael Farrell于2026年3月9日出售4 991股ResMed股票, 平均价格为251.03美元, CEO Michael Farrell sold 4,991 shares of ResMed stock on March 9, 2026, for about $1.25 million at an average price of $251.03, reducing his stake by 1.06%. 此次向SEC提交的出售案是预先安排计划的一部分，正值3月11日股价下跌2.6%，伴随着贝尔德下调的目标价以及更广泛的市场情绪。 The sale, filed with the SEC and part of a pre-arranged plan, coincided with a 2.6% drop in the stock price on March 11, amid a lowered price target from Baird and broader market sentiment. 尽管收入下降,ResMed在1月份报告收入强劲,同比收入增加11%,每股收入超过估计数。 Despite the decline, ResMed reported strong earnings in January, with revenue up 11% year-over-year and earnings per share exceeding estimates. 该公司在睡眠和呼吸道治疗设备方面保持牢固的市场地位,市场上限为351.7亿美元,长期表现呈积极趋势。 The company maintains a solid market position in sleep and respiratory therapy devices, with a market cap of $35.17 billion and a long-term positive performance trend.